Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Alogliptin

A Review of its Use in the Management of Type 2 Diabetes Mellitus

Abstract

Alogliptin (Nesina®) is a dipeptidyl peptidase-4 inhibitor that is approved in Japan for the treatment of adult patients with type 2 diabetes mellitus that is inadequately controlled by diet and exercise alone or by diet plus treatment with an α-glucosidase inhibitor. Alogliptin plus diet and exercise is also approved in Japan for use in combination with a thiazolidinedione in patients with type 2 diabetes. In several large (n > 250), double-blind, multinational trials of up to 26 weeks’ duration, oral alogliptin as monotherapy or in combination with other oral antihyperglycaemic agents (metformin, glibenclamide or pioglitazone) or insulin therapy improved glycaemic control and was generally well tolerated in adult patients with inadequately controlled type 2 diabetes, including elderly patients. Significant improvements in glycaemic control were evident from as early as 1 week in terms of improvements in mean fasting plasma glucose levels and from 4 weeks onwards for improvements in mean glycosylated haemoglobin levels. In general, the incidence of hypoglycaemia was similar to that seen in placebo groups and alogliptin treatment had neutral effects on bodyweight and lipid parameters. The long-term safety of alogliptin therapy remains to be established in clinical studies and with clinical experience. A planned clinical trial evaluating long-term clinical outcomes in patients with acute coronary syndrome and other planned or ongoing short-term trials will help to more definitively determine the position of alogliptin therapy in relation to other available antihyperglycaemic therapies. In the meantime, alogliptin is a promising new option for the treatment of patients with type 2 diabetes, including elderly patients.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Meece J. Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies. Curr Med Res Opin 2007; 23 (4): 933–44

  2. 2.

    Rosenstock J, Zinnan B. Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2007; 14: 98–107

  3. 3.

    Inzucchi SE, McGuire DK. New drugs in the treatment of diabetes. Part II: incretin-based therapy and beyond. Circulation 2008; 117: 574–84

  4. 4.

    Pratley RE, Gilbert M. Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors. Rev Diabet Stud 2008; 5 (2): 73–94

  5. 5.

    American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009; 32 Suppl. 1: 62–7

  6. 6.

    World Health Organization. Diabetes: what is diabetes? [online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs312/en/ [Accessed 2010 Mar 12]

  7. 7.

    Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc 2009; 49 Suppl. 1: S16–29

  8. 8.

    Lee B, Shi L, Kassel DB, et al. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. Eur J Pharmacol 2008; 589: 306–14

  9. 9.

    Asakawa T, Moritoh Y, Kataoka O, et al. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure. Life Sci 2009; 85 (3–4): 122–6

  10. 10.

    Moritoh Y, Takeuchi K, Asakawa T, et al. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycaemic control and beta-cell function in obese diabetic ob/ob mice. Eur J Pharmacol 2008; 588: 325–32

  11. 11.

    Moritoh Y, Takeuchi K, Asakawa T, et al. Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and β-cell function in db/db mice. Br J Pharmacol 2009; 157 (3): 415–26

  12. 12.

    Moritoh Y, Takeuchi K, Asakawa T, et al. The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. Eur J Pharmacol 2009; 602 (2–3): 448–54

  13. 13.

    Moritoh Y, Takeuchi K, Hazama M. Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta cells in prediabetic db/db mice. Diabetes Obes Metab 2010; 12 (3): 224–33

  14. 14.

    Christopher R, Covington P, Davenport M, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther 2008; 30 (3): 513–27

  15. 15.

    Covington P, Christopher R, Davenport M, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther 2008; 30 (3): 499–512

  16. 16.

    Data on file, Takeda Pharmaceutical Company Limited, 2010

  17. 17.

    Narita T, Katsuura Y, Sato T, et al. Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese type 2 diabetic patients [letter]. Diabet Med 2009; 26 (2): 187–8

  18. 18.

    Hirayama M, Matsuno K, Fujita T, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of the dipeptidyl peptidase-4 inhibitor alogliptin in Japanese healthy male subjects [abstract no. 521-P]. Diabetes 2008; 57 Suppl. 1: A155. Plus poster presented at 68th Annual Scientific Sessions of the American Diabetes Association; 2008 Jun 6-10; San Francisco (CA)

  19. 19.

    Karim A, Fleck P, Harrell Jr RE, et al. Effects of age, race, and gender on the pharmacokinetics and pharmacodynamics of alogliptin, a novel and highly selective dipeptidyl peptidase-4 inhibitor, in healthy subjects [abstract no. PI-14]. Clin Pharmacol Ther 2008 Mar; 83 Suppl. 1: 13

  20. 20.

    Covington P, Christopher R, Davenport M, et al. Lack of pharmacokinetic interaction between alogliptin benzoate (SYR-322) and metformin in healthy subjects [abstract no. 2136-PO]. 67th Annual Scientific Sessions of the American Diabetes Association; 2007 Jun 22–26; Chicago (IL), 541–2

  21. 21.

    Karim A, Copa A, Fleck P, et al. Effects of alogliptin on the pharmacokinetics and pharmacodynamics of norethindrone and ethinyl estradiol (Ortho-Novum®1/35) in healthy adult female subjects [abstract no. PI-16]. Clin Pharmacol Ther 2008; 83 Suppl. 1: 14

  22. 22.

    Karim A, Chiselko P, Fleck P, et al. Lack of effect of cyclosporine on the single-dose pharmacokinetics of alogliptin, a novel dipeptidyl peptidase-4 inhibitor, in healthy male subjects [abstract no. PI-15]. Clin Pharmacol Ther 2008; 83 Suppl. 1: 13

  23. 23.

    Karim A, Fleck P, Harris S, et al. Lack of pharmacokinetic interaction between multiple doses of the dipeptidyl peptidase-4 inhibitor alogliptin and digoxin in healthy subjects [abstract no. PI-13]. Clin Pharmacol Ther 2008; 83 Suppl. 1: 12–3

  24. 24.

    Karim A, Fleck P, Harris S, et al. Assessment of drug interaction between alogliptin, a highly selective dipeptidyl peptidase-4 inhibitor, and atorvastatin in healthy subjects [abstract no. PI -17]. Clin Pharmacol Ther 2008; 83 Suppl. 1: 14

  25. 25.

    Karim A, Laurent A, Munsaka M, et al. Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants. J Clin Pharmacol 2009; 49 (10): 1210–9

  26. 26.

    Karim A, Fleck P, Hetman L, et al. Single-dose pharmacokinetics of the dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment [abstract no. 538-P]. Diabetes 2008; 57 Suppl. 1: A160. Plus poster presented at the 68th Annual Scientific Meeting of the American Diabetes Association; 2008 Jun 6–10; San Francisco (CA)

  27. 27.

    Nesina® tablets 25mg, 12.5mg and 6.25mg: Japanese prescribing information. Osaka: Takeda Pharmaceutical Company Limited, 2010

  28. 28.

    DeFronzo RA, Fleck PR, Wilson CA, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 2008; 31 (12): 2315–7

  29. 29.

    Fleck P, Christopher R, Covington P, et al. Efficacy and safety of alogliptin monotherapy over 12 weeks in patients with type 2 diabetes [abstract no. 479-P]. Diabetes 2008; 57 Suppl. 1: 143. Plus poster presented at the 68th Annual Scientific Meeting of the American Diabetes Association; 2008 Jun 6–10; San Francisco (CA)

  30. 30.

    Pratley RE, Reusch JE, Fleck PR, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 2009; 25 (10): 2361–71

  31. 31.

    Pratley RE, Kipnes MS, Fleck PR, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabet Obes Metab 2009; 11 (2): 167–76

  32. 32.

    Nauck MA, Ellis GC, Fleck PR, et al. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract 2009; 63 (1): 46–55

  33. 33.

    Rosenstock J, Rendell MS, Gross JL, et al. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1C without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab 2009; 11 (12): 1145–52

  34. 34.

    Pratley RE, McCall T, Fleck PR, et al. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J Am Geriatr Soc 2009; 57 (11): 2011–9

  35. 35.

    Japanese Pharmaceutical and Medical Devices Agency. Report of the Council for the Evaluation of Licensing Divsion Pharmaceutical and Food Bureau. Nesina® tablets 6.25 mg, 12.5 mg and 25 mg [online]. Available from URL: http://www.info.pmda.go.jp/shinyaku/g100410/40025600_22200AMX00309000_A100_2.pdf [Accessed 2010 Sep 16]

  36. 36.

    Burant C, Fleck P, Wilson C, et al. Effect of alogliptin combined with pioglitazone on beta cell function and insulin resistance in metformin-treated patients with type 2 diabetes [abstract no. 2023-PO]. 45th Annual Meeting of the European Association for the Study of Diabetes; 2009 Sep 29–Oct 2; Vienna

  37. 37.

    Takeda Pharmaceutical Company Limited. Approval of additional indication of Nesina®: combination therapywith thiazolidinediones for type 2 diabetes in Japan [online]. Available from URL: http://www.takeda.com/press/article_37852.html [Accessed 2010 Aug 25]

  38. 38.

    Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32 (1): 193–203

  39. 39.

    Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials. A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 2009; 53 (3): 298–304

  40. 40.

    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352 (9131): 837–53

  41. 41.

    Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359 (15): 1577–89

  42. 42.

    The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358 (24): 2545–59

  43. 43.

    The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358 (24): 2560–72

  44. 44.

    American Diabetes Association. Standards of medical care in diabetes: 2009. Diabetes Care 2009; 32 Suppl. 1: S13–61

  45. 45.

    National Institute for Health and Clinical Excellence. Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes. NICE clinical guidelines 87 [online]. Available from URL: http://www.nice.org.uk/nicemedia/live/12165/44318/44318.pdf [Accessed 2009 Jul 26]

  46. 46.

    IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006; 23 (6): 579–93

  47. 47.

    Fowler MJ. Diabetes treatment, Part 2: oral agents for glycaemic management. Clin Diabetes 2007; 25 (4): 131–4

  48. 48.

    Lipscombe LL. Thiazolidinediones: do harms outweigh benefits? CMAJ 2009; 180 (1): 16–7

  49. 49.

    Falchetti A, Masi L, Brandi ML. Thiazolidinediones and bone. Clin Cases Mineral Bone Metab 2007; 4 (2): 103–7

  50. 50.

    Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009; 180 (1): 32–9

  51. 51.

    Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins). Clin Pharmacokinet 2010; 49 (9): 573–88

  52. 52.

    Takeda Pharmaceutical Company Limited. Takeda submits application in Japan for additional indications of alogliptin combination therapy with sulphonylurea and combination therapy with biguanide [online]. Available from URL: http://www.takeda.com/press/article_35896.html [Accessed 2010 Jul 19]

  53. 53.

    Takeda Pharmaceutical Company Limited. Takeda submitted an application for an additional indication of alogliptin for combination therapy with thiazolidinediones, and a new drug application of fixed-dose combination of alogliptin and pioglitazone HCl in Japan [online]. Available fromURL: http://www.takeda.com/press/article_34816.html [Accessed 2010 Jul 19]

  54. 54.

    Pratley RE. Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Expert Opin Pharmacother 2009; 10 (3): 503–12

  55. 55.

    Takeda Pharmaceutical Company Limited. Takeda receives new information on alogliptin (SYR-322) NDA [online]. Available from URL: http://www.takeda.com/press/article_32750.html [Accessed 2010 Jul 15]

  56. 56.

    FierceBiotech. PPD announces Takeda to conduct additional study for alogliptin MAA in the EU [online]. Available from URL: http://www.fiercebiotech.com/pressreleases/ppd-announces-takeda-conduct-additional-studyalogliptin-maa-eu [Accessed 2010 Jul 15]

  57. 57.

    Takeda Global Research and Development Center Inc. A multicenter, randomized, double-blind study to evaluate the efficacy and safety of alogliptin compared to glipizide in elderly subjects with type 2 diabetes [ClinicalTrials.gov identifier NCT00707993]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 Mar 12]

  58. 58.

    Takeda Global Research and Development Center Inc. A long-term, open-label extension study to investigate the long-term safety of SYR110322 (SYR-322) in subjects with type 2 diabetes [ClinicalTrials.gov identifier NCT00306384]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 Mar 12]

  59. 59.

    Takeda Global Research and Development Center Inc. A comparative, randomized, open-label, multicenter, single dose pharmacokinetic, pharmacodynamic and safety study of alogliptin (12.5 mg and 25 mg) between children, adolescents and adults, with type 2 (non-insulin dependent) diabetes mellitus [ClinicalTrials.gov identifier NCT00957268]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 Mar 12]

  60. 60.

    Takeda Global Research and Development Center Inc. A multicenter, randomized, double-blind, active-controlled study to evaluate the durability of the efficacy and safety of alogliptin compared to glipizide when used in combination with metformin in subjects with type 2 diabetes [Clinical Trials.gov identifier NCT00856284]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 Mar 12]

  61. 61.

    Takeda Global Research and Development Center Inc. A multicenter, randomized, double-blind, placebo-controlled study to evaluate cardiovascular outcomes following treatment with alogliptin in addition to standard of care in subjects with type 2 diabetes and acute coronary syndrome [ClinicalTrials.gov identifier NCT00968708]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 Mar 12]

  62. 62.

    Takeda Global Research and Development Center Inc. A multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of alogliptin plus metformin, alogliptin alone, or metformin alone in subjects with type 2 diabetes [ClinicalTrials.gov identifier NCT01023581]. US National Institutes of Health, Clinical Trials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 Mar 12]

  63. 63.

    Wajchenberg BL. β-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007; 28 (2): 187–218

  64. 64.

    Kendall DM, Cuddihy RM, Bergenstal RM. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. Am J Med 2009; 122: 37–50

  65. 65.

    Merck & Co. Inc. Januvia® (sitagliptin) tablets: US prescribing information [online]. Available from URL: http://www.merck.com/product/usa/pi_circulars/j/januvia_pi.pdf [Accessed 2010 Jul 15]

Download references

Author information

Correspondence to Lesley J. Scott.

Additional information

An erratum to this article is available at http://dx.doi.org/10.2165/11585290-000000000-00000.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Scott, L.J. Alogliptin. Drugs 70, 2051–2072 (2010). https://doi.org/10.2165/11205080-000000000-00000

Download citation

Keywords

  • Metformin
  • Pioglitazone
  • Glycaemic Control
  • Sitagliptin
  • Less Square Mean